Axiom ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-2708-A75R

Tirzepatide · Lot RVA-TR-318A13
Issued Oct 25, 2026 PT · v1
Verify: 8A47-EBF8-DF32


SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

L1	L2	L3	L4	L8
Identity	Purity	Net Peptide Content	Sterility	Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A · right

Brand	**Peptides For Less**	Product	**Tirzepatide**
Lot / Batch	**RVA-TR-318A13**	Label Claim	**30 mg**
Matrix	**Lyophilized powder**	Sample Count	**1**
Vial Size	**3mL**	Cap Color	**Blue**
Crimp Color	**Silver / Aluminum**	Contents Color	**White**
Seal Intact	**Yes**	Condition	**sealed, intact**
Received	**Oct 1, 2026 PT**	Sampling	**client submitted**

Test Results

Test	Specification	Result	
Identity research screen	every vial within ±1 Da of 4813.527 Da	4813.487 Da	PASS
Purity research screen	≥ 99.25 area %	99.98%	PASS
Net Peptide Content research screen	every vial within ±10% of 30 mg	Vial A: 31.7 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Peptides

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

SCAN TO VERIFY

AX-2026-2708-A75R


Tirzepatide · Lot RVA-TR-318A13
Issued Oct 25, 2026 PT · v1
Verify: 8A47-EBF8-DF32

Layer Results

1 Identity
LC-MS (ESI+)

4813.487 Da
every vial within ±1 Da of 4813.527 Da
PASS

Theoretical mass	**4813.527 Da**	Acceptance	**within ±1 Da**
Vial A	**4813.487 Da · PASS**		



2 Purity
RP-HPLC 214nm (USP <621>)

99.98%
≥ 99.25 area %
PASS


Acceptance	**≥ 99.25%**	Vial A	**99.98% · PASS**
Criterion source	**Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31**		



3 Net Peptide Content
Quantitative HPLC vs reference std

Vial A: 31.7 mg
every vial within ±10% of 30 mg
PASS

Target	**30 mg (±10%)**	Vial A	**31.7 mg · PASS**



4 Sterility · Rapid PCR
Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected
Rapid PCR screen
PASS

Target panel	**Pan-bacterial 16S rRNA gene (VIC), Pan-fungal 18S rRNA gene (FAM)**

Run controls valid.

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-2708-A75R

Tirzepatide · Lot RVA-TR-318A13
Issued Oct 25, 2026 PT · v1
Verify: 8A47-EBF8-DF32

SCAN TO VERIFY

8 Fentanyl Screen


LC-MS/MS targeted adulterant screen

none detected
no fentanyl or analog at or above 1 ng/mg

PASS

Result	**Not detected**	Detection limit	**1 ng/mg**
Analytes screened	**Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)**	Source container	**A**

LC-MS Mass Spectrum · Vial A · LC-MS (ESI+)



Recorded deconvoluted average mass: 4813.487 Da

Charge	Observed m/z	Deconvoluted mass (Da)	Relative intensity (%)
4+	1204.379	4813.487	51.9
5+	963.706	4813.496	100.0
6+	803.257	4813.499	51.9
7+	688.649	4813.491	7.3
8+	602.690	4813.462	0.3

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.


Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-2708-A75R

Tirzepatide · Lot RVA-TR-318A13
Issued Oct 25, 2026 PT · v1
Verify: 8A47-EBF8-DF32

SCAN TO VERIFY

HPLC Chromatogram · Vial A · RP-HPLC 214 nm



Peak	Retention time (min)	Area %
1	6.447	0.003
2	7.225	0.011
3	7.583	99.980
4	8.132	0.003
5	8.597	0.001
6	9.498	0.002

Reporting Scope & Limitations

[Sterility · Rapid PCR] Rapid PCR screen for microbial DNA. It detects DNA from live and dead organisms and is not a USP <71> sterility test or a USP <61> count. Full USP <71> sterility testing is available as an add-on.

[Fentanyl Screen] Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Peptides FOR LESS

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-2708-A75R

Tirzepatide · Lot RVA-TR-318A13
Issued Oct 25, 2026 PT · v1
Verify: 8A47-EBF8-DF32

SCAN TO VERIFY

Digital Signatures

Analyst	**Alana Reeves**	Analyst Signature	**ed25519:5ff6614a1f768b1ae5a1c06c...**
Technical Reviewer	**Michael Niles**	Reviewer Signature	**ed25519:9a4eb339c1cbb78197cf79fd...**
Laboratory Director	**Daniel Brennan**	Director Signature	**ed25519:cb6bd71b6d8643a23a6277d6...**

Testing is performed within Axiom's laboratory network under Axiom's methods. Every result is reviewed and released by Axiom, which issues and is responsible for this certificate. Axiom Analytics does not hold ISO/IEC 17025 accreditation. Samples are identified to the testing laboratory by an internal lot ID only. The method status of each result is shown beside it.

Each signature is an Ed25519 signature over the SHA-384 hash of this report. Scan the QR code or verify it yourself at https://axiomanalyticslab.com/verify/AX-2026-2708-A75R.

CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: 6069b7fcb26c3336beec2c316ce64d89971c5943d79c74fd30cf07f7da32833c...

Seal: ed25519:dc25fade571e807508385a4eb61188c2de99f056...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.